Discovery Drive
Cambridge Biomedical Campus
Cambridge CB2 0AX
United Kingdom
44 12 2369 6000
https://www.abcam.com
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 1,760
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Mr. Markus Lusser | President | N/A | N/A | N/A |
Marc Leigh Russell Perkins | General Counsel & Company Secretary | N/A | N/A | N/A |
Emma Sceats | Senior Vice President of Sales & Marketing | N/A | N/A | N/A |
Ms. Alejandra Solache Ph.D. | Senior Vice President of Research & Development | N/A | N/A | N/A |
Mr. John Baker | Senior Vice President of Supply Chain & Manufacturing | N/A | N/A | N/A |
Juan Carlos Sacristan | Senior Vice President of Data & Digital | N/A | N/A | N/A |
Abcam Limited, a life science company, focuses on identifying, developing, and distributing reagents and tools for scientific research, diagnostics, and drug discovery. The company's principal products include primary and secondary antibodies; conjugated antibodies and conjugation kits; singleplex immunoassays; proteins and peptides that include cytokines; edited cell lines and lysates; and various other products, including cellular activity kits, biochemicals, and cell signaling pathway tools. It serves scientists and researchers in academic institutions and research institutes, as well as in pharmaceutical, biotechnology, and diagnostics companies. The company has operations in the Americas, Europe, the Middle East, Africa, China, Japan, and rest of the Asia Pacific. It sells its products online. Abcam Limited was formerly known as Abcam plc and changed its name to Abcam Limited in December 2023. The company was incorporated in 1998 and is headquartered in Cambridge, the United Kingdom. As of December 6, 2023, Abcam Limited operates as a subsidiary of Danaher Corporation.
Abcam Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.